BOL-148 substance abuse treatment method patent grant to Ceruvia Lifesciences
Summary
The USPTO granted patent US12594272B2 to Ceruvia Lifesciences LLC covering a method of treating substance abuse using 2-bromo-lysergic acid diethylamide (BOL-148). The patent contains 6 claims and was filed on March 25, 2021, with Carey Turnbull listed as the inventor.
What changed
The USPTO issued patent grant US12594272B2 to Ceruvia Lifesciences LLC for a method of reducing substance use by administering BOL-148 (2-bromo-lysergic acid diethylamide) to an individual. This is a granted patent with enforceable exclusive rights in the US.
Pharmaceutical companies and drug manufacturers should note this patent position when developing psychedelic-based or LSD-derivative treatments for substance use disorders. Competitors may need to pursue licensing arrangements or design-around strategies to avoid infringement.
What to do next
- Monitor for updates
- Review freedom-to-operate for BOL-148 compounds
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
2-bromo-lysergic acid diethylamide for substance abuse
Grant US12594272B2 Kind: B2 Apr 07, 2026
Assignee
Ceruvia Lifesciences LLC
Inventors
Carey Turnbull
Abstract
A method of treating substance abuses in an individual, by administering 2-bromo-lysergic acid diethylamide (BOL-148) to an individual and reducing use of the substance.
CPC Classifications
A61K 31/48 A61P 25/32
Filing Date
2021-03-25
Application No.
17913471
Claims
6
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.